Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights
May 13, 2024 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a...
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 07, 2024 16:01 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
May 01, 2024 08:00 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
The Joint Commission Enterprise Announces Four Appointments to Executive Leadership Team
April 11, 2024 12:59 ET
|
The Joint Commission
OAKBROOK TERRACE, Illinois, April 11, 2024 (GLOBE NEWSWIRE) -- (OAKBROOK TERRACE, Illinois, April 11, 2024) – Building on a strong team of healthcare leaders to support its strategic transformation...
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
April 09, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
April 01, 2024 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya™ for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for...
TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2023 Financial Results
April 01, 2024 16:05 ET
|
TOMI Environmental Solutions, Inc.
FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its...
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
March 26, 2024 08:00 ET
|
Healis Therapeutics
The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
March 21, 2024 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder ...
Nerve Tape® Study led by Top Surgeons Receives Distinction
February 14, 2024 17:10 ET
|
BioCircuit Technologies
Atlanta, GA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- BioCircuit Technologies, an NIH-supported company in Atlanta, GA, recently announced the publication of an independent study assessing Nerve Tape, the...